Terbogrel
| Code | Size | Price |
|---|
| TAR-T17039-5mg | 5mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Terbogrel is an orally available thromboxane A2 receptor antagonist. Terbogrel is a thromboxane A2 synthase inhibitor (IC50s: about 10 nM).
CAS:
149979-74-8
Formula:
C23H27N5O2
Molecular Weight:
405.502
Pathway:
GPCR/G Protein|Immunology/Inflammation
Purity:
0.98
SMILES:
CC(C)(C)NC(NC#N)=Nc1cccc(c1)C(=C/CCCC(O)=O)c1cccnc1
Target:
Prostaglandin Receptor
References
Soyka R, et al. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J Med Chem. 1999;42(7):1235-1249.
Muck S, et al. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer. Eur J Pharmacol. 1998;344(1):45-48.